Urolithin A

Research Papers and Clinical Trials

Current research on Urolithin A spans multiple therapeutic areas, with studies investigating its effects on cellular health, metabolic function, and age-related conditions.

Preclinical Research

Several recent animal studies have explored Urolithin A's therapeutic potential across different organ systems. A 2026 study in Experimental & Molecular Medicine examined Urolithin A's effects on heart failure with preserved ejection fraction (HFpEF), finding that it activates mitophagy (cellular cleanup of damaged mitochondria) through the AMPK-mTOR pathway while modulating gut-ceramide interactions to improve cardiac remodeling. Another 2026 study in Gut Microbes investigated Urolithin A's protective effects against arsenic-induced gut barrier dysfunction using humanized mice models.

Research has also focused on kidney health, with a 2026 FASEB Journal study showing that Urolithin A may reduce renal fibrosis by promoting fatty acid oxidation through β-catenin signaling. In the area of cognitive health, a 2026 Phytomedicine study found that Urolithin A supplementation improved sleep deprivation-induced cognitive impairments and anxiety in mice by reducing hippocampal ferroptosis (a form of cell death) via Nrf2 signaling pathways.

Human Clinical Trials

Multiple clinical trials are investigating Urolithin A's effects in humans, though specific sample sizes and detailed results are not provided in the available evidence. Completed studies include trials examining its effects on skeletal muscle function, iron metabolism, and endurance performance (NCT04783207), as well as studies in middle-aged adults with obesity (NCT05921266) and immune health applications (NCT05735886).

An active trial is investigating protein supplementation with or without Urolithin A during single-leg immobilization (NCT05814705), while the PROMETHEUS clinical trial protocol outlines plans to study lifestyle and nutraceutical interventions for healthy aging, potentially including Urolithin A.

Research Limitations

While these studies suggest promising therapeutic potential, the evidence base remains limited. Most mechanistic research comes from animal models, and human clinical trial results are not yet widely published. The translation of preclinical findings to human health benefits requires further investigation through well-designed clinical studies.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.